# Study to Evaluate CCS1477 in Advanced Tumours

Source: https://onco.cc/trials/nct03568656/  
OnCo record `nct03568656` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Inobrodib run by CellCentric Ltd., completed.

## Summary

Study to Evaluate CCS1477 in Advanced Tumours is a phase 1/2 interventional study registered as NCT03568656 by CellCentric Ltd., with 219 participants enrolled, started 2018-07-23, primary completion reached 2025-07-06. Conditions recorded: Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors. Interventions recorded: CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03568656
- Phase: 1/2
- Setting: An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
- Sponsor: CellCentric Ltd.
- Enrolled: 219

## Sources

- ClinicalTrials.gov NCT03568656: https://clinicaltrials.gov/study/NCT03568656

## Connected records

- drugs: [Inobrodib](https://onco.cc/drugs/inobrodib/)
- companies: [CellCentric](https://onco.cc/companies/cellcentric/)

---
JSON: https://onco.cc/api/v1/entities/nct03568656.json